LONDON, Nov. 1, 2022
/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical
technology company, today announces the introduction of
its JOURNEY II ROX Total Knee Solution – a reverse hybrid
construct for total knee arthroplasty. This new procedural product
solution aims to provide surgeons with the clinical advantage of an
advanced bearing material and anatomic design combined with the
efficiency1 and potential long-term tibia fixation of a
cementless knee.
The JOURNEY II ROX Total Knee Solution combines several of
Smith+Nephew's high performance technologies in one construct - the
characteristic kinematics2-8 of JOURNEY II TKA, the
clinical history*9,10 of CONCELOC™ Advanced
Porous Titanium and the wear resistance of OXINIUM™
Oxidized Zirconium.11-13 The JOURNEY II ROX Total
Knee Solution is also compatible with Smith+Nephew's
CORI™ Surgical System enabling surgeons to perform the
procedure using next generation robotics-assisted technology.
"The reverse hybrid combination provides my patients with a
powerful collection of knee arthroplasty technologies. The
kinematic functionality of JOURNEY II, the biocompatibility and
longevity benefits of an oxidized zirconium alloy femoral component
in OXINIUM and now CONCELOC," said Dr. Steven B. Haas, Chief, the Knee Service and John
N. Insall Chair, Knee Surgery at the Hospital for Special Surgery
in New York. "CONCELOC offers the
potential to achieve osseointegration where it is needed – the
tibia and patellae. It's an evidence-based approach to knee
arthroplasty that utilizes high performance technologies delivered
with the operative time savings recognized in a complete cementless
procedure."
"The reverse hybrid technique works very well in my hands and
I'm able to ensure my patients have the opportunity to harness the
JOURNEY II knee mechanics for a more natural knee function," said
Dr. Matthew Bullock, Associate
Professor of Orthopaedic Surgery, Marshall
University, Joan C. Edwards
School of Medicine. "The hybrid approach does not add time
to my cases - in fact, I find that using the porous tibia and
patella components reduces my operative time by approximately 15
minutes instead of waiting for cement to cure."
"Driving procedural innovation to help surgeons treat patients
and provide better outcomes is the core of our purpose - Life
Unlimited," said Randy Kilburn, Executive Vice President and
General Manager, Global Joint Reconstruction and Robotics at
Smith+Nephew. "The JOURNEY II ROX Total Knee Solution underscores
this by bringing together high performance components to deliver a
custom procedural solution that no other company offers."
Smith+Nephew will preview the JOURNEY II ROX Total Knee Solution
in its booth (#501) at the 2022 Annual Meeting of the American
Association of Hip and Knee Surgeons (AAHKS) from November 3-6 in Dallas, TX.
Smith+Nephew will also showcase at AAHKS, its 'Power Of One'
mobile exhibit - an interactive experience focused on the
capabilities of handheld robotics and computer-guided surgery using
the CORI™ Surgical System. It is small, portable, and
does not require CT or MRI, making it a well-placed solution for
hospitals, Ambulatory Surgical Centres, and Hospital Outpatient
Departments.
References
1. Yayac M, Harrer S, Hozack WJ, Parvizi J, Courtney M. The use
of cementless components does not significantly increase procedural
costs in total knee arthroplasty. J Arthroplasty.
2020;35:407-712
2. Grieco TF, Sharma A, Dessinger GM, Cates HE, Komistek RD. In
Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee
Arthroplasty and the Normal Knee Using Fluoroscopy. J Arthroplasty.
2018;33(2):565-571.
3. Iriuchishima T, Ryu K. A Comparision of Rollback Ratio
between Bicruciate Substituting Total Knee Arthroplasty and Oxford
Unicompartmental Knee Arthroplasty. J Knee Surg.
2018;31(6):568-572.
4. Murakami K, Hamai S, Okazaki K, et al. Knee kinematics in
bi-cruciate stabilized total knee arthroplasty during squatting and
stair-climbing activities. J Orthop. 2018;15(2):650-654.
5. Murakami K, Hamai S, Okazaki K, et al. In vivo kinematics of
gait in posterior-stabilized and bicruciate-stabilized total knee
arthroplasties using image-matching techniques. Int Orthop.
2018;42(11):2573-2581.
6. Smith LA, Nachtrab J, LaCour M, et al. In Vivo Knee
Kinematics: How Important Are the Roles of Femoral Geometry and the
Cruciate Ligaments? J Arthroplasty. 2021;36:1445-1454.
7. Carpenter RD, Brilhault J, Majumdar S, Ries MD. Magnetic
resonance imaging of in vivo patellofemoral kinematics after total
knee arthroplasty. Knee. 2009;16(5):332-336.
8. Catani F, Ensini A, Belvedere C, et al. In vivo kinematics
and kinetics of a bi-cruciate substituting total knee arthroplasty:
a combined fluoroscopic and gait analysis study. J Orthop Res.
2009;27(12):1569-1575
9. Moriarty P, Vles G, Haddad F, Konan
S. Early clinical and radiological outcomes of a new tapered
fluted titanium monobloc revision stem in hip arthroplasty. Act
Orthop Trauma Surg. 2021;141:1065-1071.
10. Smith+Nephew 2015. Orthopaedic Research Report
OR-14-091A.
Technology for THA. Poster presented at: 2013 Annual Meeting of
the Orthopaedic Research Society. Poster no. 1028.
11. Papannagari R, Hines G, Sprague J, Morrison M. Long-term
wear performance of an advanced bearing technology for TKA. Poster
presented at: 2011 Annual Meeting of the Orthopaedic Research
Society. Poster no. 1141.
12. DesJardins J, Burnikel B, LaBerge M. UHMWPE wear against
roughened oxidized zirconium and CoCr femoral knee components
during force-controlled simulation. Wear. 2008;264:245-256
13. Ries MD, Salehi A, Widding K, Hunter G. Polyethylene wear
performance of oxidized zirconium and cobalt-chromium knee
components under abrasive conditions. J Bone Joint Surg Am.
2002;84-A Suppl 2:129-135
*Clinical history based on Smith+Nephew's REDAPT™ Revision Hip
System
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people's bodies and their self-belief
by using technology to take the limits off living. We call this
purpose 'Life Unlimited'. Our 18,000 employees deliver this mission
every day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Sports Medicine & ENT and Advanced
Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2021.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/smithnephew-expands-procedural-innovation-with-introduction-of-journey-ii-rox-total-knee-solution-301664334.html
SOURCE Smith & Nephew plc